Article

Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A

Division of Immunology, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Rheumatology (Impact Factor: 4.44). 02/2006; 45(1):31-7. DOI: 10.1093/rheumatology/kei090
Source: PubMed

ABSTRACT To investigate the levels of the pro-inflammatory cytokines IL-6, TNF-alpha, IL-1beta, IL-8, IL-10 and IL-12p70 in the plasma of patients with TNF receptor-associated periodic syndrome (TRAPS) in relation to CRP levels and treatment with etanercept.
Cytokine concentrations were measured in sequential plasma samples obtained from eight patients with a C33Y mutation in TNFRSF1A and diagnosed with TRAPS, using cytokine bead array. The TRAPS samples were compared with samples from normal controls and rheumatoid arthritis patients.
Levels of IL-6 were significantly elevated in C33Y TRAPS patients and these correlated with CRP levels in some of the patients. IL-8 levels were also significantly elevated in the TRAPS patients. However, neither TNF-alpha nor IL-1beta demonstrated a similar increase. This differed from the patients with rheumatoid arthritis, for whom levels of IL-6, IL-8, TNF-alpha, IL-1beta and IL-10 were significantly elevated. The levels of detectable TNF-alpha in the TRAPS patients' plasma were elevated during etanercept treatment.
The cytokine profile of C33Y TRAPS differs from that of a typical autoimmune inflammatory condition such as rheumatoid arthritis, as only IL-6 and IL-8 were elevated in C33Y TRAPS patients, as distinct from a generalized elevation of pro-inflammatory cytokines. However, only some of the C33Y patients tested showed a relationship between elevated IL-6 and CRP. This is consistent with clinical observations that there is marked heterogeneity between individuals with TRAPS, including those in the same family cohort. Although etanercept has a therapeutic effect in some TRAPS patients, it induces increased plasma concentrations of TNF-alpha, possibly by increasing TNF-alpha stability.

Full-text

Available from: Patrick Tighe, Jun 13, 2014
0 Followers
 · 
89 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Le Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS), est une maladie rare qui appartient au groupe des fièvres récurrentes ou syndromes autoinflammatoires héréditaires. Le TRAPS est une affection héréditaire, transmise sur le mode autosomique dominant en rapport avec une mutation du gène TNFRSF 1A localisé sur le bras court du chromosome 12 (en 12p13), codant pour le récepteur 1A du TNF. Les manifestations du TRAPS sont classiquement caractérisées par des accès inflammatoires qui se traduisent par une fièvre associée à des douleurs abdominales, des arthralgies ou des arthrites, des myalgies, des lésions cutanées ou encore une atteinte oculaire. Ces patients ont un risque accru de développer une amylose de type AA. La corticothérapie est la base du traitement, mais elle ne permet pas de prévenir l’amylose. Le traitement par anti TNF α parait très prometteur pour réduire les accès et améliorer la qualité de vie de ces patients.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The demonstration of the quantitative prevalence of specific cytokines in JIA formed the basis for the introduction of biological anticytokine drugs to treatment. Routine assessment of the concentration of these cytokines in blood serum may enable earlier decision making on the legitimacy of biological treatment (anti-TNF). The aim of the study was to assess the diagnostic value of TNFalpha, IL-6, and IL-1beta in monitoring the course of the disease and effectiveness of treatment with etanercept of children with oligo- and polyarticular JIA.
    Clinical laboratory 01/2014; 60(9):1481-90. DOI:10.7754/Clin.Lab.2013.130734 · 1.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is a systemic disease with several major complications affecting both the quality and length of life. The disease is characterized by increasing susceptibility to infection that important risk factor for oral infection progressiveness; periodontitis, infection or lesions. Infection progressiveness and inflammation can increase blood cytokines. The cytokines modulate cells up and down regulation moreover apoptosis or necrosis cells. The increasing of the blood cytokines that implicate in the process of pancreatic β-cell destruction is not fully understood. Poor oral hygiene stimulate proinflammatory cytokines (such as: IL-1, IL6, TNF-alpha, etc.) and make chronic infection worse. IL-1β and/or TNF-α plus IFN-γ induce β-cell apoptosis via the activation of β-cell gene networks under transcription controlling factors, such as NF-κβ (nuclear factor-κβ) and STAT-1 (signal transducers and activators of transcription-1). Others mechanism of the decreased β-cell function may activate cytokines stimulated macrophages. The presence of activated macrophages within pancreatic islets in insulin-dependent diabetes mellitus suggests an involvement of ß-cell death. This paper describes that poor oral hygiene are high predisposition on the diabetic progressiveness.